Nalaganje...
Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors
BACKGROUND: HSP90 inhibition leads to proteosomal degradation of activated KIT and has in vitro activity against gastrointestinal stromal tumors (GIST). BIIB021 is an oral non-ansamycin HSP90 inhibitor. We carried out a phase II study of BIIB021 in patients with GIST refractory to imatinib and sunit...
Shranjeno v:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Oxford University Press
2013
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4023320/ https://ncbi.nlm.nih.gov/pubmed/22898035 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mds275 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|